Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220024 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy
A Phase 2 study, sponsored by Innocoll.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01220024 is a Phase 2 study that has completed, run by Innocoll. The registered enrollment target is 50 participants.
The verdict
NCT01220024, a Phase 2 study, has completed, sponsored by Innocoll.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study will assess pain intensity for the first 72 hrs after after aggravated movement (cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the CollaRx Bupivacaine implant or a plain collagen sponge.
Interventions
- DRUG Bupivacaine Collagen Sponge
- DRUG Placebo collagen Sponge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-12-02 |
| Est. Completion | 2011-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220024
The ClinicalTrials.gov registry entry for NCT01220024 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innocoll, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine Collagen Sponge is the first listed.
NCT01220024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220024 about?
NCT01220024 is a clinical study titled "Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy". This study will assess pain intensity for the first 72 hrs after after aggravated movement (cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the CollaRx Bupivacaine implant or a plain collagen sponge.
What is the current status of trial NCT01220024?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-12-02. Estimated completion is 2011-05-18.
What interventions are being tested in trial NCT01220024?
The interventions under investigation include: Bupivacaine Collagen Sponge (DRUG), Placebo collagen Sponge (DRUG).
Who is sponsoring clinical trial NCT01220024?
This trial is sponsored by Innocoll, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.